Skip to main content
SpringerLink
Log in

Short- and long-term effect of a long-acting somatostatin analogue, lanreotide (SR-L) on metastatic gastrinoma

  • Case Report
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Medical treatment is the elective therapy for patients with gastrinoma when the tumor is not found at surgery or is unresectable or when there is a metastatic disease. H2-blockers and omeprazol are able to control gastric acid secretion and, in addition, somatostatin analogues decrease gastrin levels. A new long-acting and slow release formulation of a somatostatin analogue (lanreotide, SR-L) has been developed. We treated two patients suffering from gastrinoma, total gastrectomy and hepatic metastases with 30 mg intramuscular injections of SR-L every 15 and 10 days, respectively, for a sevenmonth period. After the treatment, gastrin levels decreased from 35,494 and 15,086 ng/l to 3,211 and 167 ng/l (92 and 98% below pre-treatment levels) in case 1 and 2 respectively, with a relief of symptoms and no side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Meko J.B., Norton J.A. Management of patients with Zollinger-Ellison syndrome. Ann. Rev. Med. 46: 395, 1995.

    Article  CAS  PubMed  Google Scholar 

  2. Mozell E.J., Cramer A.J., O’Dorisio T.M., Woltering E.A. Long-term efficacy of octreotide in the treatment of Zollinger-Ellison syndrome. Arch. Surg. 127: 1019, 1992.

    Article  CAS  PubMed  Google Scholar 

  3. Blanchin M., Jaines-Deidier A., Chaumet-Riffaud Ph.D., Chayvialle L.A. Utilisation de l’octréotide dans les tumeurs endocrines digestives. Etude française multicentrique. Presse Med. 21: 697, 1992.

    CAS  PubMed  Google Scholar 

  4. Arnold R., Benning R., Neuhaus C., Rolwage M., Trautmann M.E., and the German Sandostatin Study Group. Gastroenteropancreatic endocrine tumors: effect of sandostatin on tumor growth. Metabolism 41 (SuppI. 2): 116, 1992.

    Article  CAS  PubMed  Google Scholar 

  5. Fiasse R., Pauwels S., Rahier J., Jamar F., Ketelslegersu J.M., Hassoun A., de Longueville M. Use of octeotride in the treatment of digestive neuroendocrine tumours. Seven-year experience in 20 cases including 9 cases of metastatic midgut carcinoid and 5 cases of metastatic gastrinoma. Acta Gastroenterol. Belg. 56: 279, 1993.

    CAS  PubMed  Google Scholar 

  6. Lowell A., Johnson D., Hande K., Shaff M., Win S., Krozely M., Oates J. Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol. 32: 217, 1993.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, Hospital de Cruces, Plaza de Cruces s/n, 48903, Baracaldo, Spain

    S. Gaztambide & J. A. Vazquez

Authors
  1. S. Gaztambide
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. A. Vazquez
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gaztambide, S., Vazquez, J.A. Short- and long-term effect of a long-acting somatostatin analogue, lanreotide (SR-L) on metastatic gastrinoma. J Endocrinol Invest 22, 144–146 (1999). https://doi.org/10.1007/BF03350895

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03350895

Key-words

Search

Navigation